medigraphic.com
ISSN 1684-1824 (Electronic)

2019, Number 5

<< Back Next >>

Rev Méd Electrón 2019; 41 (5)

Practical use of the laboratory in hepatic diseases

Arredondo BAE, Trujillo PY, Chiong QM

Language: Portugués
References: 28
Page: 1217-1229
PDF size: 129.02 Kb.


ABSTRACT

The physician providing health care should daily evaluate hepatic testes in persons with liver diseases, or in the so-called controls to persons supposedly healthy. The aim of this work was facilitating practical reflection in the interpretation of hepatic testes. The most important works published in MEDLINE, EMBASE and Scielo during the last years were reviewed for understanding laboratory tests in the study of hepatic lesions. In the regular practice the increase of aminotransferases has been associated to a growth of total mortality, and this one related to hepatic dysfunction. The imaging studies and also hepatic biopsy should be taking into consideration when hepatic testes do not define the diagnosis, to study the patient, or when there are many possible diagnoses; therefore defining the growth of the alaninotransferase and aspartate aminotransferase levels together with the levels of alkaline phosphatase and bilirubin in the cholestasis lesion and the use of testes measuring the cell metabolism in the hepatocellular disease or cholestasis are very important in the day-to-day medical practice.


REFERENCES

  1. Kwo PY, Cohen SM, Lim JK. ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries. Am J Gastroenterol 2017;112(1):18–35. Citado en PubMed:PMID:27995906.

  2. Helmke S, Colmenero J, Everson GT. Noninvasive assessment of liver function. Curr Opin Gastroenterol 2015;31(3):199–208. Citado en PubMed:PMID:25714706.

  3. European Association for the Study of the Liver, & European Association for the Study of Diabetes (EASD. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol.2016;64(6):1388-402. Citado en PubMed:PMID:27062661.

  4. Ruiz-Bueno P, Lavín AC, álvarez S, et al. Protocolo diagnóstico de la elevación crónica de las transaminasas. Medicine-Programa de Formación Médica Continuada Acreditado [Internet] 2016 [citado 02/08/2017];12(9):520-8. Disponible en: https://www.sciencedirect.com/journal/medicine-programa-de-formacion-medicacontinuada- acreditado/vol/12/issue/9

  5. Chalasani NP, Hayashi PH, Bonkovsky HL. ACG clinical guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol. 2014;109(7):950–66. Citado en PubMed:PMID:24935270.

  6. Ruhl CE, Everhart JE. Upper limits of normal for alanine aminotransferase activity in the United States population. Hepatology. 2012;55(2):447–54. Citado en PubMed:PMID:21987480.

  7. Chalasani N, Younossi Z, Lavine JE. The diagnosis and management of nonalcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012;55:2005–23. Citado en PubMed:PMID:22656328.

  8. Voican C S, Martin S, Verstuyft C, et al. Liver function test abnormalities in depressed patients treated with antidepressants: a real-world systematic observational study in psychiatric settings. PloS One. 2016;11(5):e0155234. Citado en PubMed:PMID:27171561.

  9. Karaphillis E, Goldstein R, Murphy S, et al. Serum alanine aminotransferase levels and all-cause mortality. Eur J Gastroenterol Hepatol 2017;29(3):284-8. Citado en PubMed:PMID:27787263.

  10. Tripathi P, Tripathi M. Biochemical assessment of liver in sickle cell disease patients at a tertiary care hospital of north India. International J Research in Med Sciences [Internet] 2016 [citado 02/08/2017];4(1):57-60. Disponible en: http://www.msjonline.org/index.php/ijrms/article/view/445

  11. Lee WM, Stravitz RT, Larson AM. Introduction to the revised American Association for the Study of Liver Diseases Position Paper on acute liver failure 2011. Hepatology [Internet] 2012[citado 02/08/2017];55:965–7. Disponible en: http://onlinelibrary.wiley.com/doi/10.1002/hep.25551/full

  12. Ceriotti F, Henny J, Queraltó J. Common reference intervals for aspartate aminotransferase (AST), alanine aminotransferase (ALT) and ã-glutamyl transferase (GGT) in serum: results from an IFCC multicenter study. Clin Chem Lab Med [Internet] 2010 [citado 04/082017];48:1593–601. Disponible en: https://www.degruyter.com/view/j/cclm.2010.48.issue- 11/cclm.2010.315/cclm.2010.315.xml

  13. Hachemi M, Benmakhlouf S, Prost P, et al. La Non Alcoholic Fatty Liver Disease (NAFLD) et la Non Alcoholic Steato-Hepatitis (NASH) des pathologies de system: revue pour le réanimateur. Médecine Intensive Réanimation [Internet] 2017 [citado 02/08/2017];26(1):63-74. Disponible en: https://link.springer.com/article/10.1007/s13546-016-1253-9

  14. Udell JA, Wang CS, Tinmouth J. Does this patient with liver disease have cirrhosis? JAMA [Internet] 2012[citado 02/08/2017];307:832–42. Disponible en: http://jamanetwork.com/journals/jama/fullarticle/1355997

  15. Petäjä E M, Yki-Järvinen H. Definitions of normal liver fat and the association of insulin sensitivity with acquired and genetic NAFLD—a systematic review. Internat J of Molecular Sciences [Internet] 2016 [citado 02/08/2017];17(5):633. Disponible en: http://www.mdpi.com/1422-0067/17/5/633/htm

  16. Swain M, Nath P, Parida P K, et al. Biochemical Profile of Nonalcoholic Fatty Liver Disease Patients in Eastern India with Histopathological Correlation. Indian J Clin Biochemistry [Internet] 2016 [citado 02/08/2017];1-9. Disponible en: https://link.springer.com/article/10.1007/s12291-016-0612-7

  17. Bell C C, Hendriks D F, Moro S M, et al. Characterization of primary human hepatocyte spheroids as a model system for drug-induced liver injury, liver function and disease. Scientific Reports [Internet] 2016 [citado 02/08/2017];6:25187. Disponible en: http://www.nature.com/articles/srep25187?WT.feed_name=subjects_hepatocytes

  18. Nielsen S M B, Vinther-Jensen T, Nielsen J E, et al. Liver function in Huntington's disease assessed by blood biochemical analyses in a clinical setting. J Neurological Sciences [Internet] 2016 [citado 02/08/2017];362:326-32. Disponible en: http://www.sciencedirect.com/science/article/pii/S0022510X16300831

  19. Haimerl M, Schlabeck M, Verloh N, et al. Volume-assisted estimation of liver function based on Gd-EOB-DTPA–enhanced MR relaxometry. European Radiology [Internet] 2016 [citado 02/08/2017];26(4):1125-33. Disponible en: https://link.springer.com/article/10.1007/s00330-015-3919-5

  20. Raczynska J, Paczek L, Habior A, et al. Biochemical and Serological Markers of Liver Function in Liver Transplant Recipients with Primary Biliary Cholangitis. J Hepatology [Internet] 2016 [citado 02/08/2017];64(2):S542. Disponible en: fhttps://www.journal-of-hepatology.eu/article/S0168-8278(16)00967-3/pdf

  21. Belli LS, Berenguer M, Cortesi PA, et al. Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study. J Hepatology [Internet] 2016 [citado 02/08/2017];65(3):524-31. Disponible en: http://www.sciencedirect.com/science/article/pii/S0168827816301969

  22. Zhang P, Wang C Y, Li Y X, et al. Determination of the upper cut-off values of serum alanine aminotransferase and aspartate aminotransferase in Chinese. World J Gastroenterology. 2015;21(8):2419. Citado en PubMed:PMID:22656328.

  23. Zoppini G, Cacciatori V, Negri C, et al. The aspartate aminotransferase-to-alanine aminotransferase ratio predicts all-cause and cardiovascular mortality in patients with type 2 diabetes. Medicine 2016;95(43): Citado en PubMed:PMID: 5089086.

  24. Krawczyk M, Zimmermann S, Hess G, et al. Correction: Panel of three novel serum markers predicts liver stiffness and fibrosis stages in patients with chronic liver disease. PloS One;2017;12(6):e0179205. Citado en PubMed:PMID:28575071

  25. Bhargava S, Singh N, Matreja P S, et al. Radiological and Biochemical aspect of Alcoholic Liver Disease: A Prospective study. Annals of Applied Bio-Sciences [Internet] 2016 [citado 02/08/2017];3(1):A22-26. Disponible en: https://www.pacificejournals.com/journal/index.php/aabs/article/view/aabs642

  26. Scherzer R, Heymsfield S B, Rimland D, et al. Association of serum albumin and aspartate transaminase with 5-year all-cause mortality in HIV/hepatitis C virus coinfection and HIV monoinfection. AIDS [Internet] 2017 [citado 2/08/2017];31(1):71-9. Disponible en: http://www.ingentaconnect.com/content/wk/aids/2017/00000031/00000001/art0 0008

  27. Biegus J, Hillege H L, Postmus D, et al. Abnormal liver function tests in acute heart failure: relationship with clinical characteristics and outcome in the PROTECT study. Eur J Heart Fail 2016;18(7):830-9. Citado en PubMed:PMID:27170455

  28. Antunes A G, Teixeira C, Vaz A M, et al. Comparación del valor pronóstico de los modelos del Chronic Liver Failure Consortium y modelos tradicionales para predecir la mortalidad en pacientes con cirrosis. Gastroenterología y Hepatología [Internet] 2017 [citado 4/08/2017];40(4):276-85. Disponible en: https://medes.com/publication/119861




2020     |     www.medigraphic.com